SCHEMBL538069

SCHEMBL538069

Fc1nc2ccccc2cc1Cl

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.52
GLA P06280 3/20 0.52
HPGD P15428 3/20 0.52
MAPT P10636 1/20 0.52
ACHE P22303 1/20 0.52
KMT2A Q03164 2/20 0.46
KDM4E B2RXH2 5/20 0.44
TDP1 Q9NUW8 3/20 0.41
MBNL1 Q9NR56 1/20 0.41
GAA P10253 2/20 0.39
HTR3A P46098 1/20 0.39
STAT3 P40763 1/20 0.39
NQO2 P16083 1/20 0.39
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
LMNA P02545 1/20 0.38
POLB P06746 1/20 0.38
PTBP1 P26599 1/20 0.38
RCE1 Q9Y256 1/20 0.38
ALOX5 P09917 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL244868 0.77 KMT2A (0.59) ALDH1A1GLAHPGDMAPTACHE
SCHEMBL29911341 0.77 KMT2A (0.59) ALDH1A1GLAHPGDMAPTACHE
SCHEMBL2172354 0.77 ALDH1A1 (0.56) ALDH1A1GLAHPGDMAPTACHE
SCHEMBL31278632 0.76 KMT2A (0.57) ALDH1A1GLAHPGDMAPTACHE
SCHEMBL28217575 0.75 ALDH1A1 (0.48) ALDH1A1GLAHPGDMAPTACHE
SCHEMBL3300463 0.74 TLR8 (0.53) ALDH1A1GLAHPGDMAPTACHE
SCHEMBL538053 0.74 ALDH1A1 (0.59) ALDH1A1GLAHPGDMAPTACHE
SCHEMBL17274766 0.74 ALDH1A1 (0.52) ALDH1A1GLAHPGDMAPTACHE
SCHEMBL8400543 0.74 ALDH1A1 (0.52) ALDH1A1GLAHPGDMAPTACHE
SCHEMBL538070 0.74 KMT2A (0.55) ALDH1A1GLAHPGDMAPTACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0641341-B1 METHOD FOR PREPARING BENZO [b]NAPHTHYRIDINES RHONE POULENC RORER SA (FR) 2000-03-01 EP claimed
US-5484921-A Process for preparing benzo[b]naphthyridines LABORATOIRE ROGER BELLON (FR) 1996-01-16 US claimed
US-8598159-B2 Therapeutic pyrazoloquinoline derivatives DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2013-12-03 US disclosed
EP-2166852-B1 THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES HELICON THERAPEUTICS INC (US) 2012-02-08 EP disclosed
US-20110065693-A1 THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES HELICON THERAPEUTICS, INC. (US) 2011-03-17 US disclosed
US-7872002-B2 Therapeutic pyrazoloquinoline derivatives HELICON THERAPEUTICS, INC. (US) 2011-01-18 US disclosed
CN-101742908-A therapeutic pyrazoloquinoline derivatives HELICON THERAPEUTICS INC 2010-06-16 CN disclosed
EP-2166852-A1 THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES Helicon Therapeutics, Inc. (US) 2010-03-31 EP disclosed
WO-2008154438-A1 THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES HELICON THERAPEUTICS, INC. (US) 2008-12-18 WO disclosed
US-20080306049-A1 THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES HELICON THERAPEUTICS, INC. (US) 2008-12-11 US disclosed
EP-0861864-B1 Method of preparation of polyquinolines HITACHI CHEMICAL CO LTD (JP) 2004-08-25 EP disclosed
US-5786071-A Method of preparation of polyquinolines HITACHI CHEMICAL COMPANY, LTD. (JP) 1998-07-28 US disclosed
US-5723573-A ACETYLENIC END GROUPS HITACHI CHEMICAL COMPANY, LTD. (JP) 1998-03-03 US disclosed
US-5648448-A Method of preparation of polyquinolines HITACHI CHEMICAL COMPANY, LTD. (JP) 1997-07-15 US disclosed
US-5484921-A Process for preparing benzo[b]naphthyridines LABORATOIRE ROGER BELLON (FR) 1996-01-16 US disclosed
US-5484921-A Process for preparing benzo[b]naphthyridines LABORATOIRE ROGER BELLON (FR) 1996-01-16 US disclosed
US-5442070-A Derivatives of fluoro-quinoline carboxylic-3-acid and preparation therefor LABORATOIRE ROGER BELLON (FR) 1995-08-15 US disclosed
EP-0641341-A1 METHOD FOR PREPARING BENZO b]NAPHTHYRIDINES LABORATOIRE ROGER BELLON (FR) 1995-03-08 EP disclosed
EP-0538101-A1 Process for the preparation of benzo(b)naphthyridines LABORATOIRE ROGER BELLON (FR) 1993-04-21 EP disclosed
WO-1993007145-A1 METHOD FOR PREPARING BENZO[b]NAPHTHYRIDINES LABORATOIRE ROGER BELLON (FR) 1993-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306049-A1 THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES GABRA5, GABRB1, GABRB2 ALDH1A1 587/4885GLA 4673/4885HPGD 1684/4885
US-20110065693-A1 THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES GABRA5, GABRB1, GABRB2 ALDH1A1 587/4885GLA 4673/4885HPGD 1684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.